Authors randomly allocated 1,385 participants to four groups --- 551 to GMRx2, 276 to telmisartan–indapamide, 282 to telmisartan–amlodipine, and 276 to amlodipine–indapamide groups ...
Some results have been hidden because they may be inaccessible to you